Highlights•Breast cancer in young women should be treated based on stage and biology of
disease.•Management of breast cancer in young women requires special considerations …

Purpose Adjuvant ovarian function suppression (OFS) in premenopausal hormone receptor
(HR) positive breast cancer (BC) improves survival. Adherence to adjuvant gonadotropin …

For over 50 years of azapeptide synthetic techniques, developments have renewed the field
of peptidomimetic therapeutics. Azapeptides are close surrogates of natural peptides: they …

Purpose Although combining aromatase inhibitors (AI) with gonadotropin-releasing
hormone agonists (GnRHa) is becoming more common, it is still not clear if GnRHa is as …

Introduction Premenopausal patients with hormone receptor-positive breast cancer require
ablation therapy via a pharmacological or surgical approach. Data comparing outcomes …

Background Ovarian function suppression (OFS) is indicated in premenopausal women with
early or metastasis breast cancer, which may be achieved with similar effect by …

The use of peptides as therapeutic agents is a widespread strategy in the medicinal field, in
part due to pharmacological properties conferred by their three-dimensional structures …

Аннотация Адъювантная эндокринная терапия является неотъемлемым компонентом
лечения резектабельного люминального рака молочной железы. Стандартом в …

芳香化酶抑制剂(AIs) 只能用于绝经后乳腺癌患者.≥ 60 岁或卵巢切除术后是公认的绝经标准;
而< 60 岁的停经患者在美国国家综合癌症网指南, AIs 国际临床研究方案及有关教科书中都要求 …

Purpose: We examined whether there were differences in major depression outcomes and
independent risk factors associated with gonadotropin-releasing hormone agonists …